Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer.
作者信息
Harbeck Nadia, Heinemann Volker, Loibl Sibylle, Untch Michael
机构信息
Frauenklinik der Technischen Universität München, Klinikum Rechts der Isar, Berlin, Germany.
出版信息
Breast Care (Basel). 2008;3(s1):7-12. doi: 10.1159/000119744. Epub 2008 Apr 24.
Abstract
摘要
相似文献
1
Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer.
Breast Care (Basel). 2008;3(s1):7-12. doi: 10.1159/000119744. Epub 2008 Apr 24.
2
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Cancer Res. 2007 Feb 1;67(3):1170-5. doi: 10.1158/0008-5472.CAN-06-2101.
3
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
J Clin Oncol. 2008 Jun 20;26(18):2999-3005. doi: 10.1200/JCO.2007.14.0590. Epub 2008 May 5.
4
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
Oncotarget. 2017 Jul 19;8(35):58847-58864. doi: 10.18632/oncotarget.19375. eCollection 2017 Aug 29.
5
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. doi: 10.1073/pnas.0602468103. Epub 2006 May 8.
6
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
Jpn J Clin Oncol. 2010 Nov;40(11):999-1013. doi: 10.1093/jjco/hyq084. Epub 2010 Jun 11.
7
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Cancer Res. 2006 Feb 1;66(3):1640-7. doi: 10.1158/0008-5472.CAN-05-2000.
8
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.
Core Evid. 2005;1(2):77-87. Epub 2005 Jun 30.
9
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
Biol Open. 2020 Jan 24;9(1):bio047662. doi: 10.1242/bio.047662.
10
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
J Clin Oncol. 2005 Aug 10;23(23):5305-13. doi: 10.1200/JCO.2005.16.584. Epub 2005 Jun 13.
本文引用的文献
1
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.
2
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030.
3
Lapatinib-associated toxicity and practical management recommendations.
Oncologist. 2007 Jul;12(7):756-65. doi: 10.1634/theoncologist.12-7-756.
4
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Cancer Res. 2007 Feb 1;67(3):1170-5. doi: 10.1158/0008-5472.CAN-06-2101.
5
Blood-brain barrier delivery.
Drug Discov Today. 2007 Jan;12(1-2):54-61. doi: 10.1016/j.drudis.2006.10.013. Epub 2006 Nov 13.
6
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320.
7
Lapatinib: current status and future directions in breast cancer.
Oncologist. 2006 Nov-Dec;11(10):1047-57. doi: 10.1634/theoncologist.11-10-1047.
8
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Drugs Today (Barc). 2006 Jul;42(7):441-53. doi: 10.1358/dot.2006.42.7.985637.
9
Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Cancer. 2006 Aug 15;107(4):696-704. doi: 10.1002/cncr.22041.
10
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Clin Cancer Res. 2006 Jan 15;12(2):424-31. doi: 10.1158/1078-0432.CCR-05-1807.
Zotero 插件